It said Ranbaxy uses active pharmaceutical ingredients (API) "from unapproved sources, blends unapproved API with approved API, and uses less API in its drug than had been approved by the FDA. But since its investigation began in early 2007, the FDA has approved 18 Ranbaxy drugs for the USA, PEPFAR has bought $9 million of its HIV drugs (not certified in the USA) and distributed more than 1.8 million packages to 15 countries, mainly in Africa. Part of the reason for FDA inertia may be the stature of Ranbaxy, the largest Indian drug maker, valued at over $4 billion (although shares fell roughly 10 percent after the FDA announcement) and probably the tenth-largest maker in the world of generics (copies of formerly-patented drugs). The USA accounts for 28 percent of its sales. Ranbaxy says that "except for issues that have already been fully aired with the US government, it "knows of no evidence to support the Justice Department case – and no charges have yet been laid.